The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 23, 2019
Filed:
Aug. 31, 2016
Applicant:
Sunshine Lake Pharma Co., Ltd., Dongguan, Guangdong, CN;
Inventors:
Xinye Yang, Dongguan, CN;
Changwei Huang, Dongguan, CN;
Facheng Ma, Dongguan, CN;
Ji Zhang, Dongguan, CN;
Xiaojun Wang, Dongguan, CN;
Yingjun Zhang, Dongguan, CN;
Assignee:
SUNSHINE LAKE PHARMA CO., LTD., Dongguan, Guangdong, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 215/48 (2006.01); C07D 215/02 (2006.01); C07D 235/08 (2006.01); C07D 237/28 (2006.01); C07D 249/18 (2006.01); C07D 261/20 (2006.01); C07D 263/54 (2006.01); C07D 209/04 (2006.01); C07D 291/08 (2006.01); C07D 263/56 (2006.01); C07D 317/64 (2006.01); C07D 231/56 (2006.01); C07D 333/54 (2006.01); C07D 333/62 (2006.01); C07D 235/06 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 209/08 (2006.01); C07D 209/10 (2006.01); C07D 277/64 (2006.01); C07D 209/30 (2006.01); C07D 307/79 (2006.01); C07D 307/82 (2006.01); C07D 209/42 (2006.01); C07D 213/79 (2006.01); C07D 215/06 (2006.01); C07D 215/16 (2006.01); C07D 215/18 (2006.01); C07D 237/30 (2006.01); C07D 277/56 (2006.01); C07D 307/83 (2006.01); C07D 307/84 (2006.01); C07D 307/85 (2006.01); C07D 317/68 (2006.01); C07D 333/70 (2006.01); C07D 405/04 (2006.01); A61K 31/33 (2006.01); A61K 31/404 (2006.01); A61K 31/343 (2006.01); A61K 31/36 (2006.01); A61K 31/381 (2006.01); A61K 31/4192 (2006.01); A61K 31/42 (2006.01); A61K 31/428 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/277 (2006.01); A61K 31/416 (2006.01); A61K 31/4184 (2006.01); A61K 31/423 (2006.01); A61K 31/426 (2006.01); A61K 31/4418 (2006.01); A61K 31/443 (2006.01); A61K 31/502 (2006.01); A61K 45/06 (2006.01); C07C 255/57 (2006.01); A61K 31/47 (2006.01); A61P 13/02 (2006.01);
U.S. Cl.
CPC ...
C07D 215/48 (2013.01); A61K 31/277 (2013.01); A61K 31/33 (2013.01); A61K 31/343 (2013.01); A61K 31/36 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/416 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/42 (2013.01); A61K 31/423 (2013.01); A61K 31/426 (2013.01); A61K 31/428 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/443 (2013.01); A61K 31/4418 (2013.01); A61K 31/47 (2013.01); A61K 31/502 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61P 13/02 (2018.01); C07C 255/57 (2013.01); C07D 209/04 (2013.01); C07D 209/08 (2013.01); C07D 209/10 (2013.01); C07D 209/30 (2013.01); C07D 209/42 (2013.01); C07D 213/79 (2013.01); C07D 215/02 (2013.01); C07D 215/06 (2013.01); C07D 215/16 (2013.01); C07D 215/18 (2013.01); C07D 231/56 (2013.01); C07D 235/06 (2013.01); C07D 235/08 (2013.01); C07D 237/28 (2013.01); C07D 237/30 (2013.01); C07D 249/18 (2013.01); C07D 261/20 (2013.01); C07D 263/54 (2013.01); C07D 263/56 (2013.01); C07D 277/56 (2013.01); C07D 277/64 (2013.01); C07D 291/08 (2013.01); C07D 307/79 (2013.01); C07D 307/82 (2013.01); C07D 307/83 (2013.01); C07D 307/84 (2013.01); C07D 307/85 (2013.01); C07D 317/64 (2013.01); C07D 317/68 (2013.01); C07D 333/54 (2013.01); C07D 333/62 (2013.01); C07D 333/70 (2013.01); C07D 405/04 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07C 2602/06 (2017.05); C07C 2602/08 (2017.05);
Abstract
Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.